Hikma Pharmaceuticals (LSE:HIK) is now a FTSE 250 company because its share price fell hard enough to push it out of the FTSE 100. The quarterly FTSE index review, announced on 4 March 2026, relegated the generic and specialty drugmaker alongside easyJet. At that point, Hikma's shares were down 42% over the previous year. The main trigger was the company's full-year results on 26 February 2026, when the 2026 guidance fell well short of market hopes.
The Business did not collapse. Hikma remains profitable and cash-generative, with more than $3bn of annual revenue. What changed was the market's view of how fast it can grow, especially in US injectables. It was not promoted back in the September 2026 review.
Since then, the half-year figures published on 6 August showed core profit growth ahead of Revenue growth, and management reiterated its full-year targets. On 24 September the company named a new chief financial officer.
From FTSE 100 to mid-cap: what went wrong
Hikma's (LSE:HIK) results for the year to 31 December 2025 were solid. Revenue rose 7% to $3,349m and core operating profit increased 3% to $741m. Core Earnings Per Share rose 2% to 228 cents, and the full-year Dividend was raised 5% to 84 cents.
The outlook was the problem. For 2026 Hikma guided to constant-currency revenue growth of 2% to 4% and core operating profit of $720m to $770m. Market expectations had been for about $784m. Injectables, the group's largest division, was guided to low single-digit revenue growth and a core Operating Margin of 27% to 28%. The market had been expecting a margin of about 30.5% and injectables growth of about 8%.
Hikma also withdrew its medium-term group guidance and its injectables margin target after a review led by Said Darwazah, who took over as chief executive in December 2025. The shares fell almost 16% to 1,390p on results day. A $250m buyback for 2026, announced alongside the results, did little to steady them.
How the three divisions make money
Hikma reports three segments. Injectables made $1,423m of revenue in 2025 and supplies hospital medicines in the US, Europe and the Middle East and North Africa (MENA). Branded, with 2025 revenue of $849m, sells branded generics and in-licensed medicines, mainly across MENA. Hikma Rx, formerly the Generics division, made $1,037m and sells non-injectable generic medicines in the US. The company describes itself as the seventh-largest supplier of generic medicines in the US by volume.
The mix gives some diversification, with MENA growth offsetting US pricing pressure. The strategic review concluded that injectables needs more spending on sales, marketing, R&D and Supply chain. That Investment is the main reason near-term margins have been reset lower.
Half-year numbers show steadier progress
In its interim results for the six months to 30 June 2026, Hikma reported revenue of $1,728m, up 4% on a reported basis and 3% at constant currency. Core operating profit rose 9% to $405m and core Basic Earnings Per Share rose 5% to 128 cents. The Interim Dividend was increased 6% to 38 cents.
The divisions performed very differently. Branded revenue rose 15% to $502m and its core operating profit rose 23%, and management now expects Branded growth at the top end of its 6% to 8% range. Hikma Rx revenue slipped 1% to $520m, but its core operating profit rose 16%. Injectables revenue was flat at $685m and its core operating profit fell 8% to $189m, a margin of 27.6%.
The company reiterated all of its 2026 guidance. Operating Cash Flow rose 33% to $214m. By 5 August Hikma had bought back $227m of the $250m programme. Net Debt rose to $1,694m, which the company put at 1.9 times core EBITDA.
Investment, Leadership and the US Manufacturing angle
Hikma is also spending on its US manufacturing base, a reasonable response to the risk of US tariffs on imported generic medicines. It is upgrading its Facility in Bedford, Ohio, with commercial production expected in 2028. In the first half the group made 48 product submissions and 43 launches, and R&D spending rose 18%. A notice issued on 22 September said Hikma intends to spend about 5% to 6% of revenue on R&D in future.
The leadership line-up has changed significantly. Said Darwazah has given up the executive chair role to focus on being chief executive, and Victoria Hull has become chair. Two deputy chief executive roles were created: Mazen Darwazah covers MENA and Khalid Nabilsi covers North America and Europe. On 24 September Hikma said Rebecca Hall, previously chief financial officer of ViiV Healthcare, will join as CFO in the first quarter of 2027. Mr Nabilsi will step down from the board on 31 December 2026, and Areb Kurdi is acting CFO in the meantime. Hikma is also winding down its 503B compounding business, which it has classified as held for sale.
What mid-cap status means, and the risks
Relegation mainly affects who owns the shares. Funds that track the FTSE 100 have to sell, while FTSE 250 trackers and mid-cap managers become natural buyers. As one of the larger members of the FTSE 250, Hikma could be promoted again at a future quarterly review if its Market Value recovers enough.
Several risks remain. Injectables is growing slowly while Hikma invests heavily, so a recovery in margins depends on that spending paying off. The US generics market is still exposed to price erosion and competition. US trade policy on imported medicines is uncertain. Net debt has risen because of the buyback. Much of the Branded division's growth comes from MENA markets, which carry currency and geopolitical risks.
What to watch next
The next milestones are three R&D investor seminars on 20 October, 24 November and 16 December, followed by the full-year 2026 results, which are likely in late February 2027 based on past practice. Investors will look for whether core operating profit lands within the $720m to $770m range, whether the injectables margin stays at 27% to 28%, whether the company sets new medium-term targets, and whether it announces further Capital returns once the current buyback is finished.
The Bottom Line
Hikma is in the FTSE 250 because of a sharp fall in its share price, not because the business has stopped working. The company is still profitable, pays a rising dividend and has so far met a guidance range that disappointed the market. Against that, injectables margins are under pressure, net debt is higher and the management team is still bedding in. Whether Hikma returns to the FTSE 100 will depend largely on whether the new investment in injectables leads to faster growth.






Please wait processing your request...